Centiva Capital, LP Aldeyra Therapeutics, Inc. Transaction History
Centiva Capital, LP
- $4.65 Billion
- Q4 2024
A detailed history of Centiva Capital, LP transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Centiva Capital, LP holds 1,000 shares of ALDX stock, worth $2,240. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,000Holding current value
$2,240% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding ALDX
# of Institutions
130Shares Held
37.6MCall Options Held
757KPut Options Held
539K-
Perceptive Advisors LLC New York, NY9.28MShares$20.8 Million1.54% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$12.3 Million17.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.76MShares$8.42 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$8.11 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.47MShares$3.29 Million0.17% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $131M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...